CEO William Sibold stated, "we ended our first full year on the market at nearly $1 billion in net sales and solidified Rezdiffra as the foundational therapy in MASH." Sibold highlighted that the U.S.

Robert Michael, CEO & Chairman of the Board, reported "record net sales and exceeded our financial commitments, advanced our pipeline across all stages of development and acquired new sources of ...